CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2799 decisions of limitations and stop processing Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19

In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy. IVM safety profile and IVM wide spectrum enables to move forward with the investigation in patients infected by SARS-CoV-2 as a proof-of-concept of its possible use in the management of patients with COVID-19, given the current pandemic situation.

NCT04381884 COVID-19 Drug Treatment Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.

Primary Outcomes

Description: Number of patients in whom the SARS-CoV-2 viral load decreases after Ivermectin treatment

Measure: Reduction in SARS-CoV-2 viral load

Time: 1 - 5 days

Secondary Outcomes

Description: Clinical symptoms will be assessed after the treatment with the study drug

Measure: Number of patients with partial or complete response in COVID-19 clinical symptoms

Time: 1 - 7 days

Description: Effect of Ivermectin therapy on severity indicators such as need of intensive care unit and assisted ventilation, or mortality

Measure: Number of patients with worsening in the clinical condition

Time: 1 - 7 days

Description: Ivermectin safety profile will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE version 4.0)

Measure: Number of patients with adverse events as a measure of safety and tolerability

Time: 1 month

Measure: Ivermectin concentrations measured in plasma

Time: 1 month

Description: Effect of Ivermectin therapy on the onset of SARS-CoV-2 antibodies through the determination of serological changes

Measure: Evaluation of reactivity of the antibodies against SARS-CoV-2

Time: 1 month

Other Outcomes

Measure: Observed effects to Ivermectin serum concentrations quantified at different treatment time points.

Time: 1 month

No related HPO nodes (Using clinical trials)